Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Risk factors for secondary primary malignancies in HCC patients included older age at diagnosis, localized disease, smaller tumor size, and treatment with local tumor destruction, hepatectomy, and transplantation.   

Major finding: A total of 1,593 HCC patients (3.95%) developed secondary primary malignancies starting at 2 months after their initial HCC diagnoses; the top five sites were lung and bronchus; prostate, non-hodgkin lymphoma, colon, and breast.

Study details: The data come from a retrospective study of 40,314 adults with hepatocellular carcinoma who were diagnosed between 2000 and 2014 and identified through the SEER database who were followed for a median of 19 months from their initial HCC diagnoses.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Kong J et al. Front Oncol. 2021 Aug 23. doi: 10.3389/fonc.2021.713637. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: Raltitrexed-based transcatheter arterial chemoembolization (TACE) extended the overall survival of intermediate and advanced HCC patients in a real-world clinical setting.

Major finding: After propensity score matching, the overall survival rates at 6 months, 1 year, and 2 years were significantly higher in patients given raltitrexed compared to controls (78.2% vs 60.9%; 43.5% vs 22.8%; and 17.4% vs 2.2%, respectively).

Study details: The data come from HCC patients seen at multiple centers in Chongqing, China, between January 2013 and December 2019. Cases were divided into two groups based on treatment: the raltitrexed group (raltitrexed plus lobaplatin + pirarubicin) and the control group (lobaplatin + pirarubicin).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: He J et al. Hepatol Res. 2021 Sep 7. doi: 10.1111/hepr.13708. 

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: The postoperative controlling nutritional status (PoCONUT) score was an independent predictor of both overall survival and recurrence-free survival in small HCC patients who underwent liver resection; higher scores were associated with decreased survival.

Major finding: Overall survival at 1, 3, and 5 years was 95.4 %, 81.2, and 63.3 %, respectively, in the low PoCONUT group, vs 88.7 %, 63.0, and 44.2 %, respectively, in the high PoCONUT group (P = 0.009). Similarly, recurrence-free survival at 1, 3, and 5 years was 80.4 %, 57.5, and 49.5 %, respectively, vs 66.1 %, 40.3%, and 31.0 %, respectively, in the low and high groups.

Study details: The data come from a retrospective, case-control study including 547 consecutive adult patients with small HCC who underwent liver resection between February 2007 and December 2015; patients were divided into low (382 patients) and high (165 patients) groups according to postoperative controlling nutritional status (PoCONUT) scores (2 or less; 3 or greater).

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Peng W et al. BMC Surg. 2021 Sep 7. doi: 10.1186/s12893-021-01334-9.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: HCC patients who underwent hepatic resection had significantly higher rates of overall survival and recurrence-free survival compared to those who underwent percutaneous ablation.

Major finding: Overall survival at 1, 3, and 5 years was 97.6%, 83.6%, and 71.5%, respectively, for the hepatic resection patients, vs 89.4%, 58.5%, and 48.8%, respectively, for the percutaneous ablation patients (P = 0.032). Recurrence-free survival at these time points was 77.6%, 47.9%, and 42.6%, respectively, for the hepatic resection group, and 40.5%, 23.2%, and 15.4%, respectively, for the percutaneous ablation group (P = 0.010). 

Study details: The data come from a retrospective study of 67 adults with resectable caudate HCC within Milan criteria at three centers; 46 underwent hepatic resection and 21 underwent percutaneous ablation.

Disclosures: The study was supported by the National Science Fund for Distinguished Young Scholars, the National Natural Science Foundation of China, and the Natural Science Foundation of Guangdong, China.

Source: Xie W et al. J Gastrointest Surg. 2021 Sep 7. doi: 10.1007/s11605-021-05111-0.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: A total of 84% of HCC patients had at least one emergency department visit within 12 months of therapy.

Major finding: Patients with HCC experienced an average of 3.2 adverse events over a median of 9 months; the most common was pain (75%), followed by infection (39%). Infection was the most costly adverse event ($50,374), and up to 90% of costs were associated with inpatient admissions.

Study details: The data come from 322 adults with HCC who had 12 months of follow-up data available after treatment with tyrosine kinase inhibitor (TKI) monotherapy; immune checkpoint inhibitor (ICI) monotherapy; or FOLFOX combination therapy.

Disclosures: The study was supported by AstraZeneca and some coauthors are AstraZeneca employees. Lead author Dr. Lal had no financial conflicts to disclose.

Source: Lal LS et al. Cancer Rep. 2021 Sep 7. doi: 10.1002/cnr2.1504.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib was safe and effective in patients with advanced HCC.

Major finding: At one week after the aTACE plus apatinib procedure, levels of AST and ALT were significantly elevated compared with pre-treatment levels, indicating treatment response (65.84 U/L vs 54.15 U/L and 63.44 U/L vs 51.60 U/L, respectively). Median progression-free survival was 10.2 months, and median overall survival was 23.3 months, with longer survival in patients without portal vein tumor thrombus. 

Study details: The data come from 87 consecutive adults with advanced hepatocellular carcinoma who underwent arsenic trioxide (ATO)/lipiodol emulsion in the transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced hepatocellular carcinoma between December 2015 and February 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Li Z et al. Can J Gastroenterol Hepatol. 2021 Aug 19. doi: 10.1155/2021/5565793.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: After a median of 27 months’ follow-up, the rates of conversion therapy and both overall and progression-free survival were significantly higher in HCC patients treated with pembrolizumab-lenvatinib-TACE compared to those treated with lenvatinib-TACE.

Major finding: The rate of conversion therapy at the last follow-up was 25.7% in the pembrolizumab-lenvatinib-TACE group vs 11.1% in the lenvatinib-TACE group; median overall survival was 18.1 months in the pembrolizumab-lenvatinib-TACE group vs 14.1 months in the lenvatinib-TACE group, and median progression-free survival interval was 9.2 months in the pembrolizumab-lenvatinib-TACE group vs 5.5 months in the lenvatinib-TACE group.

Study details: The data come from a retrospective study of 142 consecutive adult patients with programmed cell death ligand-1 (PD-L1)-positive unresectable hepatocellular carcinoma who were treated with either pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) or lenvatinib-TACE sequential therapy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen S et al. J Cancer Res Clin Oncol. 2021 Aug 28. doi: 10.1007/s00432-021-03767-4.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: The overall rate of uterine perforation after intrauterine device (IUD) insertion was less than 1%, but higher with placement at 4-8 weeks postpartum compared to 9-36 weeks postpartum.

Major finding:  After adjusting for multiple variables, perforation rates associated with IUDs were significantly higher when placed at 4-8 weeks vs. 9-36 weeks postpartum (0.78% versus 0.46%, P = .001). Expulsion rates were low and similar between the early and late placement groups (1.02 vs. 1.17).

Study details: The data come from a retrospective cohort study of 24,959 women who underwent insertion of an intrauterine device at a single center. A total of 430 patients had confirmed complications; 157 of these were uterine perforations and 273 were intrauterine device expulsions.

Disclosures: The study received no outside funding. Lead author Dr. Ramos-Rivera had no financial conflicts to disclose. A coauthor is supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development.

Source: Ramos-Rivera M et al. Am J Obstet Gynecol. 2021 Aug 27. doi: 10.1016/j.ajog.2021.08.028.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.

Key clinical point: No significant associations were noted between contraception choice and age, previous pregnancies, or social determinants of health, but nearly 100% of women opted for some form of contraception following a pregnancy termination.

Major finding:  Prior to pregnancy termination, 58.5% of women reported not using contraception, and 22.4% reported using a barrier or fertility awareness. After pregnancy termination, 99.7% of women chose a form of contraception, and 95.2% chose a more effective method than what they had been using. After 6 months, 85.8% were still using contraception, and 37.8% were still using a more effective method.

Study details: The data come from a cross-sectional study of 400 women who underwent termination of pregnancy over a 2-year period. Information about contraception choice was collected before pregnancy termination, at the time of termination, and at 6 months following termination.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Smith SN et al. J Obstet Gynaecol Can. 2021 Aug 27. doi: 10.1016/j.jogc.2021.07.012.